GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-29	NT$21.30	-0.70%	142,273
26-10-29	NT$21.45	-0.23%	48,703
26-10-28	NT$21.50	0.00%	62,366
26-10-27	NT$21.50	+0.23%	86,428
26-10-22	NT$21.45	-1.38%	73,146

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 2026-10-30			5-day change	1st Jan Change
21.30 ^TWD	-0.70%		-0.70%	-17.28%

Aug. 13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 02	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI

Market Cap	2.4B 73.45M 65.78M 60.51M 54.83M 102M 6.97B 104M 722M 290M 3.67B 276M 270M 11.57B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.18B 66.72M 59.75M 54.96M 49.8M 93.09M 6.33B 94.83M 655M 263M 3.33B 250M 245M 10.51B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

Aug. 13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Aug. 02	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
Jun. 10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
May. 14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
Mar. 23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
Mar. 13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Dec. 08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
Nov. 24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
Nov. 14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
25-10-29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
25-08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 day	-0.70%
1 week	-0.70%
Current month	-4.70%
1 month	-1.84%
3 months	-3.40%
6 months	-9.36%
Current year	-17.28%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news: GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Price Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	20.9	22.05
1 month	20.9	23.55
Current year	20.9	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	2018-12-31
Dih Fen Wu DFI	Director of Finance/CFO	-	2009-12-31
Yao Hua Lue IRC	Investor Relations Contact	-	2012-11-11

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	2001-01-31
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	2012-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-0.70%	-0.70%	-6.78%	-26.93%	74.06M
WUXI APPTEC CO., LTD.	-0.62%	+0.50%	+33.92%	+60.07%	64.38B
ARGENX SE	+0.35%	+3.04%	+12.64%	+83.62%	56.16B
LONZA GROUP AG	+0.53%	+2.55%	+13.90%	+104.77%	54.16B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	45.33B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.25B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	40.78B
GENMAB A/S	+3.27%	+47.40%	+110.44%	+94.92%	33.8B
CELLTRION, INC.	+1.22%	-1.39%	+13.92%	+46.95%	32.25B
WUXI BIOLOGICS (CAYMAN) INC.	-1.29%	-1.72%	+21.00%	-6.85%	23.57B
Average	+0.01%	+4.18%	+46.76%	+144.85%	39.28B
Weighted average by Cap.	+0.01%	+3.64%	+49.43%	+162.20%

	2024	2025
Net sales	14.7M 451K 404K 371K 336K 629K 42.78M 640K 4.43M 1.78M 22.5M 1.69M 1.65M 70.97M	37.86M 1.16M 1.04M 956K 866K 1.62M 110M 1.65M 11.4M 4.58M 57.95M 4.35M 4.26M 183M
Net income	-230M -7.04M -6.3M -5.8M -5.25M -9.82M -668M -10.01M -69.16M -27.76M -352M -26.42M -25.86M -1.11B	-235M -7.21M -6.46M -5.94M -5.38M -10.06M -684M -10.25M -70.82M -28.43M -360M -27.05M -26.48M -1.14B
Net Debt	-442M -13.55M -12.13M -11.16M -10.11M -18.9M -1.29B -19.26M -133M -53.43M -677M -50.85M -49.77M -2.13B	-220M -6.73M -6.03M -5.55M -5.03M -9.39M -639M -9.57M -66.15M -26.55M -336M -25.27M -24.73M -1.06B